Higher Peritoneal Protein Clearance as a Risk Factor for Cardiovascular Disease in Peritoneal Dialysis Patient

Tae Ik Chang, Ea Wha Kang, Yong Kyu Lee, Sug Kyun Shin

Department of Internal Medicine, NHIC Medical Center, Ilsan Hospital, Goyangshi, Gyeonggi–do, Republic of Korea

Abstract

Background and Aims: Although a number of studies have been published on peritoneal protein clearance (PrCl) and its association with patient outcomes, the results have been inconsistent. Therefore, the intent of this study was to evaluate the impact of PrCl on cardiovascular disease (CVD) and mortality in peritoneal dialysis (PD) patients.

Methods: This prospective observational study included a total of 540 incident patients who started PD at NHIC Ilsan Hospital, Korea from January 2000 to December 2009. Two different types of analyses such as intention-to-treat and as-treated were used.

Results: Correlation analyses revealed that PrCl was positively correlated with diabetes, pulse pressure, C–reactive protein (CRP) level, dialysate/plasma creatinine ratio (D/P cr) at 4 h, and peritoneal Kt/V urea. PrCl was inversely correlated with serum albumin and triglyceride levels. On multivariate analysis, serum albumin, pulse pressure, D/P cr at 4 h, and peritoneal Kt/V urea were found to be independent determinants of PrCl. A total of 129 (23.9%) patients in intention-to-treat analysis and 117 (21.7%) patients in as-treated analysis developed new cardiovascular events. Time to occurrence of cardiovascular event was significantly longer in patients with a value of PrCl below the median (89.4 ml/day). In multivariate analysis, older age, presence of diabetes or previous CVD, and higher PrCl were independent predictors of cardiovascular events. Patients above the median value of PrCl had a significantly lower rate of survival than those below the median. However, a higher PrCl was not associated with increased mortality in multivariate Cox analysis.

Conclusions: A higher PrCl is a risk for occurrence of cardiovascular event, but not mortality in PD patients. Large randomized clinical trials are warranted to confirm this finding.

Introduction

Peritoneal dialysis (PD) is an established treatment modality in end-stage renal disease (ESRD) patients and approximately 150,000 patients are being maintained on PD worldwide [1]. In Korea, PD was introduced in the early 1980s and has been performed in many centers so far. Currently, more than 7500 Korean patients are maintained on PD. Recently, there have been significant improvements in patient outcomes due to advances such as the optimization of the adequacy of dialysis, management of blood pressure and anemia, and the maintenance of biochemical parameters within the target range. However, their morbidity and mortality have been much higher than those of the general population. Specifically, cardiovascular disease (CVD) is the most important cause of hospitalization and death in this population. Therefore, the management of CVD is one of the primary goals in treating patients with ESRD on PD [2]. Although the pathogenesis of CVD in PD patients is complicated and not completely understood, non-traditional as well as traditional risk factors such as diabetes, hypertension, smoking, and dyslipidemia are all associated with the high prevalence of CVD in PD patients [3]. Chronic inflammation and malnutrition are risk factors specifically related to ESRD patients on chronic PD which play a pivotal role in the development of CVD in these patients [4].

Although waste products are cleared during dialysis treatment, nutrients are also lost into the dialysate. Patients on PD may lose approximately 9–12 g of total protein and 6–8 g of albumin daily through the peritoneal membrane [5,6]. Variability in peritoneal protein loss both within and between patients is high, which can be explained by the dependency of protein transport on both the effective peritoneal surface area (the number of mainly small pores) and the intrinsic size-selective permeability (the diameter of the large pores) [7]. Protein loss during dialysis is usually compensated for by an increase in albumin synthesis in PD patients [8]. However, this process can be suppressed in cases of coexisting inflammation and malnutrition. In addition, the type of peritoneal membrane transport might influence the amount of protein loss. Protein loss is much greater in patients with a fast peritoneal solute transport rate than in those with a low solute transport rate [9]. Fast peritoneal solute transport rates have also been associated with hypoalbuminemia [10], inflammation [11], mortality, and technique failure [12–14] in some studies, but this is not always the case [15–17].
During the last decade, a number of studies have been published on peritoneal protein clearance (PrCl) and its association with outcomes in PD patients [18–25]. In some studies, PrCl has been shown to be associated with a higher prevalence of CVD and increased mortality in PD patients [18–22]. However, other studies have found no association between PrCl and an increased in cardiovascular events or mortality [23–25]. Therefore, the intent of this study was to investigate the impact of PrCl on mortality and the occurrence of cardiovascular events and to identify the determinants of PrCl in a large prospective cohort of incident patients who were on PD for at least six months.

**Methods**

**Ethics statement**

The study was carried out in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Ilsan Hospital Clinical Trial Center. We obtained informed written consent from all participants involved in our study.

**Patients and data collection**

We considered all of 620 patients who started PD at NHIC Ilsan hospital, one of the largest PD centers in Korea, from January 2000 to December 2009. We then excluded patients that were younger than 18 years of age at initiation of PD, patients that had less than 6 months of follow-up, and patients that had been on hemodialysis or received a kidney transplant before PD. Patients that recovered kidney function or started PD for other reasons, such as acute renal failure or congestive heart failure, were also excluded from the analysis. Therefore, this prospective observational study included a total of 540 incident patients finally. All of the patients underwent a peritoneal equilibration test, measurement of dialysis adequacy, and a 24-h dialysate PrCl analysis within three months of PD initiation. Demographic and clinical data were collected at the beginning of PD. The data recorded included age, gender, body mass index (BMI) calculated as weight/height$^2$, duration of PD, cause of ESRD, prevalence of diabetes and CVD, blood pressure, and patient outcomes. Laboratory data obtained at the time of dialysis adequacy measurement were considered baseline values and included blood urea nitrogen, serum creatinine, total cholesterol, serum triglyceride, serum albumin concentrations, serum C-reactive protein (CRP) levels, Kt/V urea, percentage of lean body mass (%LBMI), normalized protein catabolic rate (nPCR), residual glomerular filtration rate (GFR), and 24-h residual urine volume. Residual GFR was calculated as the average urea and creatinine clearance from a 24-h urine collection [26].

Peritoneal dialysate protein losses were measured from the collection of 24-h peritoneal dialysate effluent by the pyrogallol red method. Serum and dialysate concentrations of urea, creatinine, glucose, and albumin were all measured by a colorimetric method (UniCel DXC 800; Beckman Coulter, Inc., California, USA). To calculate PrCl, the total 24-h dialysate protein loss was divided by a validated correction factor (serum albumin/0.4783) which has been used in other previous studies [22,23]. PrCl was expressed as ml of plasma cleared per day.

**Statistical analysis**

All values are expressed as mean ± standard deviation or percentages. Statistical analyses were performed using SPSS for Windows version 13.0 (SPSS, Inc., Chicago, IL, USA). Data were analyzed using Student’s t-test and the chi-square test. The relationship between PrCl and continuous variables was examined by Pearson’s correlation coefficient, and categorical variables were examined using Spearman’s R test. Multiple linear regression analysis was performed to identify the determinants of PrCl using two different models with or without serum albumin because of the fact that serum albumin levels inevitably interfered in the estimation of PrCl. Primary outcomes were death and newly developed cardiovascular events, which were defined as coronary artery disease (angioplasty, coronary artery bypass graft, myocardial infarction, or angina), cerebrovascular disease (transient ischemic attack, stroke, or carotid endarterectomy), and peripheral artery disease (revascularization or amputation). We used both intention-to-treat and as-treated analyses. In the former, we followed patients from the date of dialysis initiation to the earlier of death or December 31, 2011. In the latter, we followed patients from the date of dialysis initiation to the earlier of death, change to hemodialysis (38 patients), renal transplantation (36 patients), loss to follow-up (29 patients), or December 31, 2011. To determine risk factors for cardiovascular events and mortality, multivariate Cox regression was performed, and all significant covariates from the univariate analysis were included. Survival was also examined by comparing patients above and below the median value of PrCl using the Kaplan-Meier method and the log-rank test. A $p$-value of less than 0.05 was considered statistically significant.

**Results**

**Demographic and clinical data**

Table 1 details baseline characteristics of the 540 incident PD patients. The mean age of the patients was 59 years (range 20 to 88 years), 53.7.1% were males, and patients were on PD for a mean of 50 months (range 6 to 142 months). The prevalence of diabetes and CVD was 53.3% and 28%, respectively. Total 24-h peritoneal protein loss was 6.7±4.4 g/day and the mean PrCl was 107.3±82.8 ml/day (median 89.4 ml/day, range 22.7 to 617.7 ml/day).

Gender, prevalence of CVD, and residual renal function (RRF) were not different between the groups when patients were divided into two groups [low and high] based on the median levels of baseline PrCl. Age (60.4±13.5 versus 57.8±14.4 years, $P=0.026$), prevalence of diabetes (58.8 versus 47.8%, $P=0.01$), serum log$_{10}$CRP level (−0.79±0.79 versus −0.95±0.71 mg/dL, $P=0.022$), D/P cr at 4 h (0.72±0.18 versus 0.64±0.16, $P=0.001$), and peritoneal Kt/V (1.5±0.6 versus 1.4±0.5, $P=0.044$) were significantly higher, while serum triglyceride level (137.3±85.5 versus 163.9±95.2 mg/dL, $P=0.001$) and albumin levels (2.9±0.5 versus 3.4±0.5 g/dL, $P<0.001$), and nPCR (0.95±0.24 versus 1.01±0.27 g/Kg/day, $P=0.004$) were significantly lower in the high PrCl group compared to the low PrCl group.

**Factors associated with peritoneal protein clearance**

Correlation analyses were performed to identify factors associated with PrCl. PrCl was positively correlated with the presence of diabetes ($\gamma=0.1, P=0.005$), pulse pressure ($\gamma=0.11, P=0.016$), log$_{10}$CRP level ($\gamma=0.096, P=0.033$), D/P cr at 4 h ($\gamma=0.13, P=0.004$), and peritoneal Kt/V urea ($\gamma=0.22, P<0.001$), whereas it was inversely correlated with serum albumin concentration ($\gamma=-0.37, P<0.001$), and triglyceride level ($\gamma=-0.09, P=0.038$). In contrast, there was no correlation between age, gender, BMI, presence of preexisting CVD, RRF, nPCR or %LBMI and PrCl. On multivariate linear regression analysis, serum albumin, D/Pcr, peritoneal Kt/V urea, and pulse pressure were independently associated with PrCl (Table 2; Model 1). In model 2, in which albumin was excluded, D/Pcr, peritoneal Kt/V urea, and pulse pressure remained in the model with the additional
Table 1. Baseline characteristics of the study subjects (n = 540).

|                               | Mean ± SD |
|-------------------------------|-----------|
| Age (years)                   | 59.1 ± 14.0 |
| Gender (Male)                 | 290 (53.7) |
| Body mass index (kg/m²)       | 22.8 ± 6.2 |
| Pulse pressure (mmHg)         | 56.6 ± 17.5 |
| Follow-up duration (months)   | 50.2 ± 33.9 |

Underlying renal disease

- Diabetes mellitus: 258 (47.8%)
- Hypertension: 155 (28.7%)
- Chronic glomerulonephritis: 76 (14.1%)
- Polycystic kidney disease: 9 (1.7%)
- Others: 15 (2.8%)
- Unknown: 27 (5.0%)

Presence of diabetes mellitus: 288 (53.3%)
Presence of prior cardiovascular disease: 151 (28.0%)

Laboratory findings

- Serum albumin (g/dL): 3.2 ± 1.6
- Total cholesterol (mg/dL): 183.6 ± 48.6
- Triglyceride (mg/dL): 150.6 ± 91.4
- CRP (mg/dL): 0.7 ± 2.6
- Peritoneal transport (D/P cr at 4 h): 0.68 ± 0.18
- Peritoneal Kt/V urea: 1.5 ± 0.6
- 24-h dialysate protein loss (g): 6.7 ± 4.4
- 24-h PrCl (mL): 107.3 ± 82.8
- 24-h residual urine volume (mL): 1083.9 ± 719.1
- Residual GFR (mL/min/1.73 m²): 6.1 ± 5.2
- nPCR (g/Kg/day): 1.0 ± 0.3
- Lean body mass (% body weight): 66.0 ± 28.5

Data are expressed as mean ± standard deviation or number of patients (percent).

CRP, C-reactive protein; D/P cr, dialysate/plasma creatinine ratio; PrCl, peritoneal protein clearance; GFR, residual glomerular filtration rate; nPCR, normalized protein catabolic rate.
doi:10.1371/journal.pone.0056223.t001

Predictors of cardiovascular events

In intention-to-treat analysis, 129 (23.9%) patients developed new cardiovascular events, which included coronary artery disease (73 patients, 56.6%), cerebrovascular disease (44 patients, 34.1%), and peripheral artery disease (12 patients, 9.3%). Additionally, in as-treated analysis, 117 (21.7%) patients developed new cardiovascular events. In both intention-to-treat and as-treated analyses, the time to occurrence of cardiovascular event was significantly longer in patients with a value of PrCl below the median (Figure 1). In the univariate Cox proportional hazards model, age, presence of diabetes or CVD, serum albumin concentration, Log¹₀ CRP level, peritoneal Kt/V urea, nPCR, %LBM, RRF, and PrCl were significantly associated with mortality. However, gender, BMI, pulse pressure, serum triglyceride level, and small solute transport status (D/Pcr at 4 h) were not associated with mortality. In multivariate analysis, older age, presence of diabetes or CVD, and hypoalbuminemia were independent predictors of mortality, whereas RRF was also identified as a significant risk factor for mortality in as-treated analysis (Figure 2).

Predictors of mortality

In intention-to-treat analysis, 203 (37.6%) deaths were recorded, and the median survival period was 42 months (range 6 to 142.2 months). CVD (37.9%) was the most common cause of death in this study, followed by infection (32.0%), unknown cause (22.7%), and others (7.4%). Additionally, in as-treated analysis, 187 (21.7%) deaths were recorded. In both intention-to-treat and as-treated analyses, patients above the median value of PrCl had a significantly lower rate of survival than those below the median (Figure 2). In the univariate Cox proportional hazards model, age, presence of diabetes or CVD, serum albumin concentration, Log¹₀ CRP level, peritoneal Kt/V urea, nPCR, %LBM, RRF, and PrCl were significantly associated with mortality. However, gender, BMI, pulse pressure, serum triglyceride level, and small solute transport status (D/Pcr at 4 h) were not associated with mortality. In multivariate analysis, older age, presence of diabetes or CVD, and hypoalbuminemia were independent predictors of mortality, whereas RRF was also identified as a significant risk factor for mortality in as-treated analysis (Table 4).

Discussion

This study, which included a total of 540 incident PD patients, is the largest one published to date on peritoneal transport of total protein and its association with patient outcomes in terms of cardiovascular events and mortality. The results demonstrated that a higher PrCl is a risk factor for occurrence of cardiovascular event, but not mortality in patients treated with PD.

Peritoneal protein clearance in PD patients reflects protein leakage across the large pores, which is equivalent to large-pore flow (JVL). Although a number of studies have been published on PrCl and its association with patient outcomes, the results have been inconsistent, and no consensus has been reached on the relationship and significance of PrCl in the development of

Table 2. Multivariate associations between peritoneal protein clearance and patient characteristics.

|                               | Model 1 | Model 2 |
|-------------------------------|---------|---------|
| PrCl (mL)                     | β       | P-value |
| Serum albumin (g/dL)          | -0.310  | <0.001  |
| D/P cr at 4 h                 | 0.134   | 0.002   |
| Peritoneal Kt/V urea          | 0.311   | <0.001  |
| Pulse pressure (mmHg)         | 0.085   | 0.046   |
| Presence of diabetes          | 0.084   | 0.062   |
| Log₁₀CRP (mg/dL)              | 0.070   | 0.106   |
| Triglyceride (mg/dL)          | 0.001   | 0.998   |

Model 1 includes albumin; model 2 excludes serum albumin.
CRP, C-reactive protein; D/P cr, dialysate/plasma creatinine ratio.
doi:10.1371/journal.pone.0056223.t002

inclusion of diabetes and increased serum CRP levels (Table 2; Model 2).
subsequent cardiovascular events and death in PD patients [18–
23]. Szeto et al. [18] showed that patients starting PD with active
CVD had higher protein and albumin levels in the peritoneal
effluent, and cardiovascular events were more frequent in patients
with greater peritoneal albumin losses. The authors postulated that
peritoneal protein losses or PrCl could be an independent
cardiovascular risk factor, and is likely associated with high
mortality in PD patients. In addition, Heaf et al. [20] found that
JvL is related to hypoalbuminemia and mortality after PD
initiation, and Van Biesen et al. [21] found that a higher JvL,
when corrected for membrane area parameter (A0/Dx), is a
marker of inflammation and is related to decreased patient
survival. Another recent study by Peal et al. [22] revealed that
increased PrCl at the start of PD is a predictor of death
independent of baseline small solute transport status, serum
albumin, age, and comorbidity. All of the above studies support
the hypothesis that protein leakage across the membrane may be a
manifestation of local or systemic inflammation as likely as
microalbuminuria, which is another manifestation of capillary
protein leakage, and is recognized as an endothelial dysfunction
marker [27]. In contrast to the aforementioned studies, no
association between PrCl and an increase in cardiovascular events
or mortality was found in other studies [23–25]. Sanchez-
Villanueva et al. [23] showed that PrCl is significantly and
independently related to the presence of peripheral artery disease,
but failed to demonstrate the association of PrCl with mortality or
subsequent cardiovascular events. In addition, a recent study by
Balafa et al. [25], which was the largest published to date, reported
that PrCl was not an independent predictor of mortality. The
authors postulated that the association of increased albumin
leakage with inflammation is only consequence of the availability
of an increased number of large pores and is not related to
endothelial dysfunction or CVD. This discrepancy between
findings is likely due to differences in study design, the number
of enrolled patients, patient characteristics, timing and methods of

![Kaplan-Meier plots of the probability of remaining cardiovascular event-free based on the median level (89.4 ml/day) of baseline peritoneal protein.](A) Intention-to-treat analysis. (B) As-treated analysis.
doi:10.1371/journal.pone.0056223.g001

**Table 3. Multivariate Cox regression analysis for cardiovascular events.**

|                      | Intention to Treat |                     | As Treated  |                     |
|----------------------|--------------------|---------------------|-------------|---------------------|
|                      | HR (95% CI)        | P-value             | HR (95% CI) | P-value             |
| Age (years)          | 1.02 (1.00–1.03)   | 0.022               | 1.02        | (1.01–1.04)         | 0.012                |
| Presence of diabetes | 1.96 (1.33–2.86)   | 0.001               | 1.95        | (1.29–2.94)         | 0.002                |
| Presence of CVD      | 1.67 (1.14–2.44)   | 0.008               | 1.72        | (1.15–2.57)         | 0.009                |
| Serum albumin (g/dL) | 0.85 (0.59–1.22)   | 0.374               | 0.74        | (0.51–1.08)         | 0.743                |
| Lean body mass (% body weight) | 0.99 (0.96–1.01) | 0.388               | 0.99        | (0.96–1.01)         | 0.367                |
| PrCl (per 10 ml/day increase) | 1.02 (1.00–1.03) | 0.041               | 1.02        | (1.00–1.04)         | 0.025                |

HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; nPCR, normalized protein catabolic rate; PrCl, peritoneal protein clearance.
doi:10.1371/journal.pone.0056223.t003
measuring PrCl, and variables included in the multivariate analysis.

This study of long term (up to 142 month) clinical outcomes of a large cohort of patients treated with PD provides strong evidence of that a higher PrCl is a risk factor for occurrence of cardiovascular event in these patients. These findings were observed consistently in both intention-to-treat and as-treated analyses. Even when we considered absolute protein losses corrected to body surface area, an association with reduced survival of remaining cardiovascular event-free persisted. On the other hand, our study on mortality does not significantly demonstrate differences according to initial PrCl. We, however, reconfirmed that older age, presence of diabetes or previous CVD, hypoalbuminemia, and lower RRF, all of which are well-known risk factors, are independent predictors of mortality in PD patients. The underlying mechanisms for these poor outcomes in patients with higher PrCl are unclear. One possible explanation could be the link between CVD and endothelial dysfunction as evidenced by microalbuminuria [27]. Here, we found that higher peritoneal protein losses or PrCl were significantly associated with lower serum albumin concentrations, which might reflect a high inflammatory and poor nutritional status [28,29] and a higher pulse pressure, which might reflect arterial stiffness and systemic vascular damage [30]. In addition, higher serum CRP values, which were available in 494 patients in this study, was also associated with higher PrCl, which although did not reach statistical significance on multivariate analysis. In line with our results, a recent cross-sectional study of prevalent PD patients from

**Figure 2.** Kaplan-Meier plots for patient survival based on the median level (89.4 ml/day) of baseline peritoneal protein clearance. (A) Intention-to-treat analysis. (B) As-treated analysis. doi:10.1371/journal.pone.0056223.g002

|                     | Intention to Treat | As Treated |
|---------------------|--------------------|------------|
|                     | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (years)         | 1.06 (1.04–1.08) | <0.001 | 1.07 (1.05–1.08) | <0.001 |
| Presence of diabetes| 1.56 (1.11–2.19) | 0.010 | 1.58 (1.10–2.25) | 0.012 |
| Presence of prior CVD| 1.61 (1.17–2.22) | 0.004 | 1.70 (1.21–2.37) | 0.002 |
| Serum albumin (g/dL)| 0.50 (0.37–0.68) | <0.001 | 0.48 (0.35–0.66) | <0.001 |
| Log<sub>10</sub>CRP (mg/dL) | 1.20 (0.97–1.48) | 0.102 | 1.19 (0.96–1.47) | 0.112 |
| Peritoneal Kt/V urea| 1.29 (0.95–1.77) | 0.108 | 1.12 (0.81–1.57) | 0.491 |
| nPCR (g/Kg/day)     | 0.80 (0.38–1.67) | 0.550 | 0.91 (0.43–1.95) | 0.813 |
| Lean body mass (% body weight) | 0.99 (0.98–1.01) | 0.317 | 1.00 (0.98–1.01) | 0.632 |
| Residual GFR (mL/min/1.73 m²) | 0.96 (0.92–1.01) | 0.106 | 0.93 (0.88–0.99) | 0.005 |
| PrCl (per 10 ml/day increase) | 1.00 (1.00–1.00) | 0.425 | 1.01 (0.99–1.03) | 0.260 |

HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; CRP, C-reactive protein; nPCR, normalized protein catabolic rate; GFR, residual glomerular filtration rate; PrCl, peritoneal protein clearance.

doi:10.1371/journal.pone.0056223.t004
Korea [31] showed that PrCl exhibited a positive correlating relationship with both heart-to-femoral pulse wave velocity implicating arterial stiffness and peripheral vascular calcium scores, which is representative of vascular calcification. Along with systemic inflammation, local inflammation may also contribute to CVD for those on PD. With high dialysate leukocyte count and IL-6 concentration, the peritoneal protein or albumin leakage has been considered to be one of these intra-peritoneal inflammation-related factors in PD patients [18,32]. Taken together, we surmised that PrCl could represent systemic or local vascular damage and endothelial dysfunction in PD patients. Another possible factor to note is that patients with a higher PrCl might have poor nutritional status. In our results, BMI, nPCR, and serum triglyceride concentration were significantly lower in patients above the median PrCl value irrespective of the presence of hypoalbuminemia. Other nutritional markers such as total cholesterol and %LBM were also lower in patients with a higher PrCl, although the differences were not statistically significant.

Based on these findings, it might be possible to postulate that these poor outcomes of patients with higher PrCl are mediated, at least partially, by the poor preserved nutritional status seen with protein-energy wasting, which has been shown to be an important predictor of morbidity and mortality in PD patients [33–35]. However, other mechanisms that remain to be explored may also play a role.

The strengths of this study are the large number of patients, the long duration of follow-up, and the adjustment for multiple potentially confounding covariates such as serum CRP. Potential limitations are the single-center design of the study and the fact that data from a full panel of peritoneal inflammation markers were not available. The lack of urinary protein excretion measurements limited the testing of possible relationships between urinary and peritoneal protein losses as a result of the common pathway of endothelial dysfunction.

**Conclusions**

This study showed that baseline PrCl is a risk factor for occurrence of cardiovascular event, but not mortality in patients on PD. These results suggest that protein leakage across the membrane may be a manifestation of a systemic or local inflammation and poor nutritional status, serving as a surrogate marker for the increased morbidity seen with malnutrition, inflammation, and atherosclerosis syndrome. A large, prospective study is required to further elucidate the association between PrCl and inflammatory or nutritional status in PD patients. Further investigations focusing on the description of changes in PrCl with time on treatment and the associated prognostic significance are also warranted.

**Author Contributions**

Conceived and designed the experiments: TIC SKS. Performed the experiments: TIC EWK. Analyzed the data: TIC YKL. Contributed reagents/materials/analysis tools: TIC SKS. Wrote the paper: TIC.

**References**

1. Grassmann A, Gieberge S, Moeller S, Brown G (2005) ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 20: 2587–2593.
2. Krediet RT, Balafa O (2010) Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 6:451–460.
3. Zoccali C (2006) Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 70:26–33.
4. Pecoiti-Filho R, Lindholm B, Steenvinkel P (2002) The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrol Dial Transplant 17(Suppl 1): S28–S31.
5. Dukkipati R, Kopple JD (2009) Causes and prevention of protein-energy wasting in chronic kidney failure. Semin Nephrol 29: 39–49.
6. Blumenkrantz MJ, Gahl GM, Kopple JD, Kamdar AV, Jones MR, et al. (1981) Protein losses during peritoneal dialysis. Kidney Int 19:593–600.
7. Rippe B (1993) A three-pore model of peritoneal transport. Perit Dial Int 13(Suppl 2): S33–S38.
8. Kaysen GA (1998) Meta-analysis: Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 9: 2368–2376.
9. Kaitharia P, Moore HL, Khanna R, Twardowski ZJ, Goel S, et al. (1997) Effect of dialysis modality and membrane transport characteristics on dialysate protein losses of patients on peritoneal dialysis. Perit Dial Int 17: 449–454.
10. Margretts PJ, McMullin J, Rabbat CG, Churchill DN (2000) Peritoneal membrane transport and hypoalbuminemia: Cause or effect? Perit Dial Int 20: 14–18.
11. Wang T, Heinburger O, Cheng HH, Bergstrom J, Lindholm B (1999) Does a high peritoneal transport rate reflect a state of chronic inflammation? Perit Dial Int 19: 17–22.
12. Churchill DN, Thorpe KE, Norph KD, Keshaviah PR, Oreopoulos DG, et al. (1998) Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 9: 1295–1299.
13. Rumpf M, McDonald SP, Johnson DW (2006) Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 17: 271–279.
14. Brimble KS, Walker M, Margretts PJ, Kundalhi KK, Rabbat CG (2006) Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591–2598.
15. Wiggins KJ, McDonald SP, Brown FG, Rossman JB, Johnson DW (2007) High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. Nephrol Dial Transplant 22: 3003–3012.
16. Johnson DW, Haslem CM, McDonald SP, Brown FG, Rosman JB, et al. (2010) Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 25: 1973–1979.
17. Rodrigues AS, Almeida M, Fonseca I, Martins M, Carvalho MJ, et al. (2006) Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation. Nephrol Dial Transplant 21: 763–769.
18. Szeto CC, Chose KM, Lam CW, Cheung R, Kwan BC, et al. (2005) Peritoneal albumin excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: A prospective cohort study. Perit Dial Int 23: 445–452.
19. Nakamoto H, Inai H, Kawanishi H, Nakamoto M, Minakuchi J, et al. (2002) Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD. Am J Nephrol 40: 1045–1054.
20. Heat JG, Sarac S, Afzal S (2005) A high peritoneal large pore fluid flux causes hypoalbuminemia and is a risk factor for death in peritoneal dialysis patients. Nephrol Dial Transplant 20: 2194–2201.
21. Van Biesen W, Van der Tol A, Veys N, Dequidt C, Vijt D, et al. (2006) The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol 1:269–274.
22. Perl J, Huckvale K, Chellar M, John B, Davies SJ (2009) Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 4: 1201–1206.
23. Eltouer R, Afsar B, Sezer S, Oezdemir FN, Haberal M (2009) Peritoneal albumin leakage: 2 year prospective cardiovascular event occurrence and patient survival analysis. Nephrology (Carlton) 14: 712–715.
24. Sanchez-Villanueva R, Bajo A, Del Peso G, Fernandez-Reyes MJ, Gonzalez E, et al. (2009) Higher daily peritoneal protein clearance when initiating peritoneal dialysis is independently associated with peripheral arterial disease (PAD): A possible new marker of systemic endothelial dysfunction? Nephrol Dial Transplant 24: 1009–1014.
25. Babula O, Halbmsa N, Struik DG, Dekker FW, Krediet RT (2011) Peritoneal albumin and protein losses do not predict outcome in peritoneal dialysis patients. Clin J Am Soc Nephrol 6: 561–566.
26. Norph KD, Moore HL, Proswant B, Meyer M, Twardowski ZJ, et al. (1993) Cross-sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 13: 178–183.
27. Weir MR (2007) Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2: 581–590.
28. de Moutert R, Groendendort DC, Indemann F, Boechtolt EW, Krediet R, et al. (2009) Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 19: 127–135.
29. Friedman AN, Fadem SZ (2010) Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 21: 223–230.
30. Malone AF, Reddan DN (2010) Pulse pressure. Why is it important? Perit Dial Int 30: 265–268.
31. Lee H, Hwang YH, Jung JY, Na KY, Kim HS, et al. (2009) Comparison of vascular calcification scoring systems using plain radiographs to predict vascular stiffness in peritoneal dialysis patients. Nephrology (Carlton) 16: 656–662.
32. Oh KH, Jung JY, Yoon MO, Song A, Lee H, et al. (2010) Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 25:1639–1646.
33. Kopple JD (1994) Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 24: 1002–1009.
34. Canada-USA (CANUSA) Peritoneal Dialysis Study Group (1996) Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 7: 190–207.
35. Han SH, Han DS (2012) Nutrition in patients on peritoneal dialysis. Nat Rev Nephrol 8: 163–175.